MiNA Therapeutics Presents New Sickle Cell Data at EHA 2025
MTL-HBG drug candidate demonstrated best-in-class activity in highly translatable pre-clinical model Data underscores transformational therapeutic potential in sickle cell disease MiNA Therapeutics Limited, the pioneer...